PHIA Koninklijke Philips N.V.

Statement of Philips CEO Frans van Houten on the COVID-19 outbreak

Statement of Philips CEO Frans van Houten on the COVID-19 outbreak

March 18, 2020

Amsterdam, the Netherlands Frans van Houten, CEO of (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on how Philips is addressing the constantly evolving coronavirus disease (COVID-19) outbreak, as its epicenter is shifting from China to the West.

COVID-19 is a top priority for Philips and all its employees. The company has mobilized its global resources to fulfill Philips’ triple duty of care: continuing to fulfill critical customer needs, ensuring the health and safety of its employees, and ensuring business continuity.

“I am proud that our employees around the world are stepping up to support healthcare providers and their patients in the fight against COVID-19,” said Frans van Houten. “We have a broad portfolio of products, services and solutions that can help address the preparedness, response and recovery needs of an infectious respiratory disease such as COVID-19.”

The complete statement by Frans van Houten can be found on .

For further information, please contact:

Steve Klink

Philips Global Press Office

Tel: 4

Email:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment

EN
18/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips successfully prices offering of Notes for EUR 1 billion to be ...

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects May 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any ...

 PRESS RELEASE

Philips Future Health Index 2025: AI poised to transform global health...

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, , highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. H...

Koninklijke Philips N.V.: 1 director

A director at Koninklijke Philips N.V. bought 8,176 shares at 24.410USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch